“With the brepocitinib CS program now moving into Phase 3 alongside the dermatomyositis and non-infectious uveitis programs, Priovant continues to advance our goal of developing brepocitinib as a ...

The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

WASHINGTON, DC – When billionaires are in the spotlight for their oversized influence in Washington, especially in the Trump administration, comes this news: Vivek Ramaswamy’s wealth has soared even ...

Company expands board of directors and makes key leadership promotions to support upcoming late-stage trials of PP405 in androgenetic alopeciaMaykin Ho, Ph.D., appointed to Pelage board of ...

Greenlight Capital's David Einhorn has been vocal about his concerns around artificial intelligence driving overvaluation in ...

Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Analysts' ratings for Roivant Sciences (NASDAQ:ROIV) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates ...